Developing potential best-in-class oral agonists of the aryl hydrocarbon receptor (AhR) agonists for ulcerative colitis.
Joined February 2019
- Tweets 4
- Following 18
- Followers 2
- Likes 3
1 Photos and videos
Adial Pharmaceuticals (NASDAQ: $ADIL) announced the acquisition of Azora Therapeutics and up to $64M PIPE. Supports Azora’s AT177, a proprietary colon-targeted AhR agonist designed to enable localized activation with limited systemic exposure.
Read more: bit.ly/3SBbWvW
1
5
Azora Therapeutics retweeted
Jun 11
.@AdialPharma announced the acquisition of @AzoraTx, bringing AT177, a colon-targeted AhR agonist, into its pipeline. The transaction is supported by a concurrent private placement of up to $64M, including $32M upfront and potential additional milestone tranches.
Adial will host a call and webcast today, June 11, 2026, at 1:00 pm ET to discuss the acquisition and financing. Dial-in: 1-877-451-6152 domestic / 1-201-389-0879 international; passcode 13761153. Webcast: bit.ly/4ejzOf5
Read more: bit.ly/3Q8x0cB
$ADIL #Acquisition #PrivatePlacement #CorporateDevelopment
1
1
1
60